Dr. Zarmeen Zahid
@zarmeen_z
Post-doctoral research fellow @JHPsychedelics | I study psychedelics and talk about it @PsychedBrainSci | All opinions here are my own | 🍉
ID: 1266920725320994816
https://www.researchgate.net/profile/Zarmeen-Zahid 31-05-2020 02:33:46
1,1K Tweet
2,2K Followers
650 Following
Paper by our very own Dr. Zarmeen Zahid 💞
New Neuropsychopharmacology paper from Dr. Rebecca Boehme The Boehme Lab Reinoud Kaldewaij @pausalamone Adam Enmalm @csan_liu Ketamine⬇️activity associated w/ self-other- touch distinction in right temporoparietal ctx, a region involved in touch perception & social cognition nature.com/articles/s4138…
Wow! The snowball effect? Or just bad timing for Lykos/MAPS? Psychopharmacology has posted retraction notices for any papers related to MAPS MP4 misconduct in Phase 2 clinical trials. This comes after a lot of time and effort by Sasha Sisko to bring attention to these events.
🔬Our new paper in Nature Reviews Psychology outlines the limitations of our understanding of psychedelics' subjective effects & how we can improve our science moving forward, going beyond just mystical experience. Proud to be a part of this with David B. Yaden, Brandon, & Roland Griffiths.
very excited that Dr. Zarmeen Zahid is now Johns Hopkins Psychedelic Research Center !
New paper published in JAMA Psychiatry: A meta-analysis of adverse events in trials of classic psychedelics suggests an overall favorable safety profile. However, serious adverse events, while rare, did occur. It highlights ways to improve the detection and reporting of adverse events